2026-05-25T12:53:05Z https://www.peertechzpublications.org/oai-pmh

oai:www.peertechzpublications.org:10.17352/aprc.000053 2020-06-23 PTZ.APRC:VOL6

Post-inflammatory pulmonary fibrosis in a discharged COVID-19 patient: Effectively treated with Pirfenidone Zhan Xi Zhao ZhigangLi Ting<p>The coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) has led to a pandemic situation. According to the WHO classification, COVID-19 patients could be classified with severity as uncomplicated illness, mild pneumonia, severe pneumonia, acute respiratory distress syndrome (ARDS), sepsis, and septic shock [1]. China has controlled the situation and thousands of patients had been discharged. We noticed that most patients of severe pneumonia or ARDS had post-inflammatory pulmonary fibrosis (PPF) during follow-up after the cure of COVID-19. Here we report a case of PPF resulting from COVID-19 effectively treated with Pirfenidone, an antifibrosis medication.&nbsp;</p><p><br></p> Archives of Pulmonology and Respiratory Care - Peertechz Publications 2020-06-23 Case Report https://doi.org/10.17352/aprc.000053 en Copyright © Zhan Xi et al.